Enjoy complimentary customisation on priority with our Enterprise License!
The global neurological biomarkers market size is estimated to grow by USD 7.82 billion at a CAGR of 13.01% between 2023 and 2028. The growth of the market is driven by several key factors, including the rising incidence of neurological disorders, the growth in clinical trials for neurological disease-specific biomarkers, and increasing initiatives and support from governments to improve access to neurological healthcare. These elements collectively propel market expansion by highlighting the growing need for advanced diagnostics and treatments, fostering research and development, and enhancing healthcare infrastructure. The rising incidence of neurological disorders underscores the urgent demand for effective medical solutions. Simultaneously, the growth in clinical trials reflects advancements in personalized medicine. Additionally, increasing government initiatives and support aim to improve healthcare accessibility and quality for neurological conditions, further driving market growth.
The market is propelled by the escalating prevalence of neurological disorders and a surge in clinical trials focusing on disease-specific biomarkers. Governments' increasing initiatives and support to enhance healthcare accessibility further stimulate market growth. However, challenges persist, including unmet market demands for the reliable validation of biomarkers, discrepancies arising from the reproducibility of biomarkers and tests, and inherent complexities within the research. These obstacles underscore the intricacies of navigating the market landscape, where balancing scientific rigor, regulatory compliance, and patient needs is imperative. Stakeholders must invest in innovative approaches to address these challenges effectively, ensuring the development of reliable biomarkers and advancing healthcare outcomes. As the market continues to evolve, strategic collaborations and regulatory reforms become crucial for fostering sustained growth and improving patient care in neurology.
To learn more about this report, Download Report Sample
The market share growth by the hospitals segment will be significant during the forecast period. Neurological disorders, including Parkinson's disease, Alzheimer's Disease (AD), dementia, brain tumors, epilepsy, and others, drive the demand for neurological biomarkers in healthcare. Hospitals, particularly large multispecialty hospitals and hospital groups, are significant end-users due to the increasing number of admissions. Medium-sized hospitals rely on outsourced medical equipment and laboratory testing support for these services. Neurological biomarkers, such as blood based biomarkers, proteomic biomarkers, microarray technology, digital biomarkers, and sleep biomarkers, aid in diagnosing neurodegenerative diseases, cardiac arrest, and other neurological conditions.
Get a glance at the market contribution of various segments Download PDF Sample
The hospitals segment was the largest and was valued at USD 2.18 billion in 2018. Physicians use these biomarkers to assess brain health and monitor treatment outcomes. Precision medicine and targeted therapies rely on reliable biomarkers for data interpretation and sample preparation in clinical diagnostics and drug development. Geriatric population, multiple sclerosis, and other neurodegenerative conditions are influenced by the aging global population and lifestyle-related factors. Healthcare providers require rapid blood tests and neuroimaging techniques for accurate diagnosis and patient privacy protection. Data analysis and laboratory techniques are essential for interpreting biomarker data and minimizing adverse effects. Such factors are expected to increase the sales of neurological biomarker products in medium-sized hospitals, which will thereby drive the growth of the hospital segment and expand the growth of the market during the forecast period.
Alzheimer's disease (AD) is a brain disorder that destroys memory and thinking skills and, eventually, the ability to carry out simple tasks. Neurological biomarkers play a significant role in therapeutic research for Alzheimer's disease (AD), providing drug targets and facilitating clinical trials. The market for these biomarkers is evolving, driven by changing lifestyle habits and the need for personalised medicine. Pharmaceutical firms are investing in clinical validations of non-invasive biomarkers, such as imaging biomarkers, for early detection of AD. Artificial intelligence and machine learning are being integrated into the development and analysis of these biomarkers to improve accuracy and efficiency. Imaging biomarkers, including amyloid and tau positron emission tomography (PET) scans, and cerebrospinal fluid (CSF) biomarkers, such as beta-amyloid and phosphorylated tau (P-tau), are essential for diagnosing AD in its pre-clinical and mild cognitive impairment (MCI) stages. The abovementioned factors are expected to drive the growth of the AD segment and will propel the growth of the market during the forecast period.
Parkinson's disease (PD) is a brain disorder that causes unintended or uncontrollable movement, such as shaking, stiffness, and difficulty with balance and coordination. The Symptoms of PD begin gradually and worsen over time. With the increasing span of time, people with PD may have difficulty walking and talking. Thus, PD is a recognizable clinical syndrome with a range of causes and clinical conditions. PD represents a fast-growing neurodegenerative condition. Various dopamine presynaptic biomarkers such as dopamine transporter (DAT) or vesicular monoamine transporter type 2 can be identified by single-photon emission computed tomography (SPECT), which could fulfill the requirement of being a useful biomarker for the treatment of PD. Thus, the development of such techniques under the Parkinsons disease segment will positively impact the growth of the market during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 40% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional market trends and drivers will shape the market during the forecast period. The increasing demand for the diagnosis of neurological disorders has boosted the demand for neurological biomarkers. For instance, an estimated 6.2 million Americans aged 65 and older lived with Alzheimers dementia in March 2021. The number could grow to 13.8 million by 2060. Also, official death certificates recorded 121,499 deaths from AD in 2019, making Alzheimers the sixth-leading cause of death in the US and the fifth-leading cause of death among Americans aged 65 and older. Thus, the high prevalence of neurological disorders, the growing aging population, high healthcare expenditure on the treatment of neurological diseases, and favorable reimbursement policies for neuro-diagnostic procedures are expected to drive the market.
In addition, the bioscience research expenditure has grown in the US and Canada. For instance, the Canadian budget for 2021 doubled down on progress made to provide USD 2.2 billion toward implementing the biomanufacturing and life sciences strategy. The funding from different societies and private organizations promotes the US and Canada to focus on drug discovery and development for neurological disorders using neurological biomarkers, which will positively impact the market during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Abbott Laboratories - The company offers neurological biomarkers namely I STAT Alinity, an easy-to-use, portable blood analyzer that delivers real time, lab quality diagnostic test results.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Neurological disorders, including Alzheimer's Disease (AD), Dementia, Brain tumors, Epilepsy, and others, pose significant challenges in diagnosis and treatment. Biomarkers, specifically blood-based biomarkers, have emerged as crucial diagnostic tools in neurology. These markers can help identify various neurological conditions at an early stage, enabling more effective treatment and better patient outcomes. Physicians rely on biomarkers for brain health assessment, particularly in conditions like AD and Dementia, where reliable biomarkers are essential for accurate diagnosis. Delayed clinical trials and adverse effects are common concerns in neurology, making the need for precise diagnostic tools and targeted therapies more pressing. Healthcare providers are increasingly adopting precision medicine approaches, which leverage biomarkers to tailor treatments to individual patients. Stroke, Autism, and Epilepsy are among the conditions that stand to benefit significantly from this trend. Rapid blood test and data interpretation are key components of this approach, ensuring timely and accurate diagnosis and treatment. Patient privacy and data security are critical considerations in the market. Ensuring the confidentiality and protection of sensitive patient information is essential to build trust and maintain the integrity of the healthcare system.
Increasing initiatives and support from governments to improve neurological healthcare access is notably driving market growth. Governments and healthcare organizations are actively working to enhance access to healthcare for individuals with neurological disorders through various initiatives. The World Health Organization collaborates with partners to improve care for individuals with epilepsy, and the Mental Health Innovation Network focuses on treating epileptic patients while combating stigma in Asia. The Welsh Government is dedicated to enhancing access to care for neurological conditions like epilepsy, cerebral palsy, and Parkinson's disease in Wales, emphasizing swift diagnosis, effective care, awareness, information improvement, and supportive research.
Moreover, initiatives like the Brain Donor Project seek funding to advance sciences for neurological disorder treatments, while the National Institute of Health's COVID-19 Neuro Databank/Biobank database tracks neurological symptoms associated with COVID-19. Increased public spending on neurological diseases, coupled with research efforts by institutions like the National Institute of Neurological Disorders and Stroke, is expected to drive the market's growth in the market forecast period.
The growing availability of blood-based biomarkers is an emerging trend shaping market growth. Neurodegenerative disorders such as AD are a public health challenge. As these diseases are difficult to diagnose clinically, biomarkers of pathophysiology play a crucial role in research, clinical trials, and the clinical work-up of the patients. In Alzheimers disease, breakthroughs in biomarker identification and validation include cerebrospinal fluid of amyloid-beta and tau proteins, which are highly accurate in detecting the presence of pathophysiological and neuropathological changes. Thus, fluid biomarkers, especially plasma-based biomarkers, are attractive as they are non-invasive and easy to obtain.
Also, emerging blood biomarkers, including amyloid beta monomers, oligomers, tau/p-tau, neurofilament light chain, and inflammatory factors, are gathering tremendous research interest. As a result of rapid advances in the development of ultrasensitive assays, the levels of pathological brain- and AD-related proteins can be measured in blood. Thus, blood-based biomarkers are emerging as an important tool to detect Traumatic brain injury (TBI), which will drive the growth of the market during the forecast period.
Inherent challenges in neurological research are a significant challenge hindering market growth. The shift of biomarkers from discovery to clinical practice is a complex procedure. The main challenges include stringent biomarker validation and testing strategies and moderate progression of the disease, requiring a high number of patients to experience long-haul treatment when traditional diagnostic parameters are utilized. Since the rise of the supposed innovation, various biomarkers have been distinguished and published, which have expanded the options for growth in the availability of more viable therapeutics. These opportunities are expected to have a significant impact on the financial aspects of healthcare services in the long term.
Furthermore, as for European neuroscientists, there is a disconnect between the growing socioeconomic need for effective therapies for brain disorders and the lack of ambition and long-term vision of neurological research in Europe. Thus, the lack of neurological research globally is expected to hinder the growth of the market during the forecast period.
The market report includes the adoption lifecycle of the market research and growth, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth and forecasting strategies.
Customer Landscape
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Million" for the period 2024 to 2028, as well as historical data from 2018 to 2022 for the following segments
Digital Biomarkers Market: Digital Biomarkers Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast
Neurodiagnostics Market: Neurodiagnostics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, China, Japan - Size and Forecast
Renal Biomarkers Market: Renal Biomarkers Market by End-user and Geography - Forecast and Analysis
The Market is a significant and growing sector in the healthcare industry. Neurological biomarkers are indicators of neurological disorders or diseases, enabling early diagnosis and effective treatment. These markers play a crucial role in understanding the disease progression and response to therapy. Key neurological disorders with identified biomarkers include Alzheimer's disease, Parkinson's disease, multiple sclerosis, and traumatic brain injury. Biomarkers for these conditions include proteins, genetic markers, and imaging techniques. For instance, beta-amyloid and tau proteins are biomarkers for Alzheimer's disease, while dopamine levels are indicators for Parkinson's disease. The market for neurological biomarkers is driven by factors such as the increasing prevalence of neurological disorders, growing awareness, and early diagnosis, and technological advancements in biomarker detection.
Additionally, regulatory approvals and collaborations between industry players and research institutions contribute to market growth. The market is segmented based on technology, application, and end-users. Technologies used for biomarker detection include imaging techniques, proteomics, and genetics. Applications include diagnosis, prognosis, and monitoring of neurological disorders. End-users include hospitals, research institutions, and diagnostic laboratories. In conclusion, the market is a dynamic and evolving sector, offering significant opportunities for growth and innovation in the diagnosis and treatment of neurological disorders.
Market Scope |
|
Report Coverage |
Details |
Page number |
175 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 13.01% |
Market Growth 2024-2028 |
USD 7.82 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
12.2 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 40% |
Key countries |
US, Germany, UK, France, and China |
Competitive landscape |
Leading Companies, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
Abbott Laboratories, ACROBIOSYSTEMS INC., Advanced Brain Monitoring Inc., Alseres Pharmaceuticals Inc, Bio Rad Laboratories Inc., bioMerieux SA, Charles River Laboratories International Inc., EATRIS ERIC, Eli Lilly and Co., Enzo Biochem Inc., F. Hoffmann La Roche Ltd., Fujirebio Holdings Inc., IQVIA Holdings Inc., Merck KGaA, Metabolon Inc., PerkinElmer Inc, Proteome Sciences plc, QIAGEN NV, Quanterix Corp., and Thermo Fisher Scientific Inc. |
Market dynamics |
Parent market growth analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period. |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Market Segmentation by Indication
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.